The Relative Value of Anti-Obesity Medications Compared to Similar Therapies

References

• Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS. 2020;360:1–8.
   Google Scholar
• Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440–2450. doi:10.1056/NEJMsa1909301
   PubMed Web of Science ®Google Scholar
• Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88. doi:10.1186/1471-2458-9-88
   PubMed Web of Science ®Google Scholar
• Haase CL, Eriksen KT, Lopes S, Satylganova A, Schnecke V, McEwan P. Body mass index and risk of obesity-related conditions in a cohort of 2.9 million people: evidence from a UK primary care database. Obes Sci Pract. 2020;7(2):137–147. doi:10.1002/osp4.474
   PubMed Web of Science ®Google Scholar
• Li Q, Blume SW, Huang JC, Hammer M, Ganz ML. Prevalence and healthcare costs of obesity-related comorbidities: evidence from an electronic medical records system in the United States. J Med Econ. 2015;18(12):1020–1028. doi:10.3111/13696998.2015.1067623
   PubMed Web of Science ®Google Scholar
• Meurling IJ, Shea DO, Garvey JF. Obesity and sleep: a growing concern. Curr Opin Pulm Med. 2019;25(6):602–608. doi:10.1097/mcp.0000000000000627
   PubMed Web of Science ®Google Scholar
• Steele CB, Thomas CC, Henley SJ, et al. Vital signs: trends in incidence of cancers associated with overweight and obesity - United States, 2005–2014. MMWR Morb Mortal Wkly Rep. 2017;66(39):1052–1058. doi:10.15585/mmwr.mm6639e1
   PubMed Web of Science ®Google Scholar
• Cawley J, Biener A, Meyerhoefer C, et al. Direct medical costs of obesity in the United States and the most populous states. J Manag Care Spec Pharm. 2021;27(3):354–366. doi:10.18553/jmcp.2021.20410
   PubMed Web of Science ®Google Scholar
• Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff. 2009;28(5):w822–W831. doi:10.1377/hlthaff.28.5.w822
   PubMed Web of Science ®Google Scholar
• Kamble PS, Hayden J, Collins J, et al. Association of obesity with healthcare resource utilization and costs in a commercial population. Curr Med Res Opin. 2018;34(7):1335–1343. doi:10.1080/03007995.2018.1464435
   PubMed Web of Science ®Google Scholar
• Kim DD, Basu A. Estimating the medical care costs of obesity in the United States: systematic review, meta-analysis, and empirical analysis. Value Health. 2016;19(5):602–613. doi:10.1016/j.jval.2016.02.008
   PubMed Web of Science ®Google Scholar
• Suehs BT, Kamble P, Huang J, et al. Association of obesity with healthcare utilization and costs in a Medicare population. Curr Med Res Opin. 2017;33(12):2173–2180. doi:10.1080/03007995.2017.1361915
   PubMed Web of Science ®Google Scholar
• Cawley J, Biener A, Meyerhoefer C, et al. Job absenteeism costs of obesity in the United States: National and State-level estimates. J Occup Environ Med. 2021;63(7):565–573. doi:10.1097/jom.0000000000002198
   PubMed Web of Science ®Google Scholar
• Finkelstein E, Fiebelkorn C, Wang G. The costs of obesity among full-time employees. Am J Health Promot. 2005;20(1):45–51. doi:10.4278/0890-1171-20.1.45
   PubMed Web of Science ®Google Scholar
• Finkelstein EA, DiBonaventura M, Burgess SM, Hale BC. The costs of obesity in the workplace. J Occup Environ Med. 2010;52(10):971–976. doi:10.1097/JOM.0b013e3181f274d2
   PubMed Web of Science ®Google Scholar
• Goetzel RZ, Gibson TB, Short ME, et al. A multi-worksite analysis of the relationships among body mass index, medical utilization, and worker productivity. J Occup Environ Med. 2010;52(Suppl1):S52–S58. doi:10.1097/JOM.0b013e3181c95b84
   PubMedGoogle Scholar
• Howard JT, Potter LB. An assessment of the relationships between overweight, obesity, related chronic health conditions and worker absenteeism. Obes Res Clin Pract. 2014;8(1):e1–e15. doi:10.1016/j.orcp.2012.09.002
   PubMed Web of Science ®Google Scholar
• Kleinman N, Abouzaid S, Andersen L, Wang Z, Powers A. Cohort analysis assessing medical and nonmedical cost associated with obesity in the workplace. J Occup Environ Med. 2014;56(2):161–170. doi:10.1097/jom.0000000000000099
   PubMed Web of Science ®Google Scholar
• Waters H, Graf M. The costs of chronic disease in the U.S; 2018. Available from: https://milkeninstitute.org/sites/default/files/reports-pdf/ChronicDiseases-HighRes-FINAL.pdf. Accessed October 20, 2021.
   Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203. doi:10.4158/ep161365.Gl
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25):2985–3023. doi:10.1016/j.jacc.2013.11.004
   PubMed Web of Science ®Google Scholar
• Bailey-Davis L, Wood GC, Benotti P, et al. Impact of sustained weight loss on cardiometabolic outcomes. Am J Cardiol. 2022;162:66–72. doi:10.1016/j.amjcard.2021.09.018
   PubMed Web of Science ®Google Scholar
• Wood GC, Bailey-Davis L, Benotti P, et al. Effects of sustained weight loss on outcomes associated with obesity comorbidities and healthcare resource utilization. PLoS One. 2021;16(11):e0258545. doi:10.1371/journal.pone.0258545
   PubMed Web of Science ®Google Scholar
• Cawley J, Meyerhoefer C, Biener A, Hammer M, Wintfeld N. Savings in medical expenditures associated with reductions in body mass index among US Adults with obesity, by diabetes status. Pharmacoeconomics. 2015;33(7):707–722. doi:10.1007/s40273-014-0230-2
   PubMed Web of Science ®Google Scholar
• Ding Y, Fan X, Blanchette CM, Smolarz BG, Weng W, Ramasamy A. Economic value of non surgical weight loss in adults with obesity. J Manag Care Spec Pharm. 2021;27(1):37–50. doi:10.18553/jmcp.2020.20036
   PubMed Web of Science ®Google Scholar
• Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes. 2005;29(10):1153–1167. doi:10.1038/sj.ijo.0802982
   PubMed Web of Science ®Google Scholar
• Ghanemi A, Yoshioka M, St-Amand J. Broken Energy homeostasis and obesity pathogenesis: the surrounding concepts. J Clin Med. 2018;7(11). doi:10.3390/jcm7110453
   PubMed Web of Science ®Google Scholar
• Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82(1Suppl):222s–225s. doi:10.1093/ajcn/82.1.222S
   PubMed Web of Science ®Google Scholar
• Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. Can Med Assoc J. 2020;192(31):E875–E891. doi:10.1503/cmaj.191707
   PubMed Web of Science ®Google Scholar
• Bray GA, Ryan DH. Evidence-based weight loss interventions: individualized treatment options to maximize patient outcomes. Diabetes Obes Metab. 2021;23(Suppl 1):50–62. doi:10.1111/dom.14200
   PubMedGoogle Scholar
• Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754–762. doi:10.1111/dom.14280
   PubMed Web of Science ®Google Scholar
• Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424–2434. doi:10.1001/jama.2016.7602
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–1413. doi:10.1001/jama.2021.1831
   PubMed Web of Science ®Google Scholar
• Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107(10):1755–1767. doi:10.1016/j.jada.2007.07.017
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, Phase 3 trial. Lancet. 2011;377(9774):1341–1352. doi:10.1016/s0140-6736(11)60205-5
   PubMed Web of Science ®Google Scholar
• Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605. doi:10.1016/s0140-6736(10)60888-4
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. NEJM. 2015;373(1):11–22. doi:10.1056/NEJMoa1411892
   PubMed Web of Science ®Google Scholar
• Ara R, Blake L, Gray L, et al. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health Technol Assess. 2012;16(5):iii–xiv, 1–195. doi:10.3310/hta16050
   Web of Science ®Google Scholar
• Lacey LA, Wolf A, O’Shea D, Erny S, Ruof J. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes. 2005;29(8):975–982. doi:10.1038/sj.ijo.0802947
   Web of Science ®Google Scholar
• Neovius M, Narbro K. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. Int J Obes. 2008;32(12):1752–1763. doi:10.1038/ijo.2008.189
   PubMed Web of Science ®Google Scholar
• Zohrabian A. Clinical and economic considerations of antiobesity treatment: a review of orlistat. Clinicoecon Outcomes Res. 2010;2:63–74. doi:10.2147/ceor.s5101
   PubMedGoogle Scholar
• Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res. 1999;7(6):523–531. doi:10.1002/j.1550-8528.1999.tb00709.x
   PubMedGoogle Scholar
• Ciciurkaite G, Moloney ME, Brown RL. The incomplete medicalization of obesity: physician office visits, diagnoses, and treatments, 1996–2014. Public Health Rep. 2019;134(2):141–149. doi:10.1177/0033354918813102
   PubMed Web of Science ®Google Scholar
• Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacotherapy. 2013;33(12):1299–1307. doi:10.1002/phar.1342
   PubMed Web of Science ®Google Scholar
• MacEwan J, Kan H, Chiu K, Poon JL, Shinde S, Ahmad NN. Antiobesity medication use among overweight and obese adults in the United States: 2015–2018. Endocr Pract. 2021;27(11):1139–1148. doi:10.1016/j.eprac.2021.07.004
   PubMed Web of Science ®Google Scholar
• Samaranayake NR, Ong KL, Leung RY, Cheung BM. Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007–2008. Ann Epidemiol. 2012;22(5):349–353. doi:10.1016/j.annepidem.2012.01.001
   PubMed Web of Science ®Google Scholar
• Saxon DR, Iwamoto SJ, Mettenbrink CJ, et al. Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009–2015. Obesity. 2019;27(12):1975–1981. doi:10.1002/oby.22581
   PubMed Web of Science ®Google Scholar
• Xia Y, Kelton CML, Guo JJ, Bian B, Heaton PC. Treatment of obesity: pharmacotherapy trends in the United States from 1999 to 2010. Obesity. 2015;23(8):1721–1728. doi:10.1002/oby.21136
   PubMed Web of Science ®Google Scholar
• Baum C, Andino K, Wittbrodt E, Stewart S, Szymanski K, Turpin R. The challenges and opportunities associated with reimbursement for obesity pharmacotherapy in the USA. Pharmacoeconomics. 2015;33(7):643–653. doi:10.1007/s40273-015-0264-0
   PubMed Web of Science ®Google Scholar
• Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018;6(3):237–248. doi:10.1016/s2213-8587(17)30236-x
   PubMed Web of Science ®Google Scholar
• Gomez G, Stanford FC. US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Int J Obes. 2018;42(3):495–500. doi:10.1038/ijo.2017.287
   PubMed Web of Science ®Google Scholar
• Jannah N, Hild J, Gallagher C, Dietz W. Coverage for obesity prevention and treatment services: analysis of Medicaid and state employee health insurance programs. Obesity. 2018;26(12):1834–1840. doi:10.1002/oby.22307
   PubMed Web of Science ®Google Scholar
• IQVIA Insitute. IQVIA SMART internal database; 2022.
   Google Scholar
• Kabiri M, Sexton Ward A, Ramasamy A, et al. The societal value of broader access to antiobesity medications. Obesity. 2020;28(2):429–436. doi:10.1002/oby.22696
   PubMed Web of Science ®Google Scholar
• Health Action Council (UnitedHealth Care U, OptumRx). Finding the uncommon: revealing disparities in care and prescribing for common conditions; 2021. Available from: https://healthactioncouncil.org/getmedia/cd194241-db0a-4db0-81c9-cfedc980b3f5/HAC-White-Paper.pdf. Accessed January 12, 2023.
   Google Scholar
• Evernorth. Drug trend report; 2020. Available from: https://www.evernorth.com/drug-trend-report. Accessed January 12, 2023.
   Google Scholar
• IQVIA Insitute. Medicine spending and affordability in the United States: understanding patients’ costs for medicines; 2020. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-spending-and-affordability-in-the-us. Accessed January 12, 2023.
   Google Scholar
• Blue Cross Blue Shield Association and Blue Health Intelligence. Prescription drug costs trend update; 2018. Available from: https://www.bcbs.com/sites/default/files/file-attachments/health-of-america-report/HoA-Rx-Costs-Trend-Update.pdf. Accessed January 12, 2023.
   Google Scholar
• IngenioRx. Taking a total view: linking pharmacy + medical drug trends. Commercial Report; 2017. Available from: https://uploads-ssl.webflow.com/59d2aa5c83887e00019716cc/5aec7315d0dbd43962508a77_2017%20Total%20View%20Drug%20Trend%20Report20180504.pdf. Accessed January 1, 2023.
   Google Scholar
• Kaiser Family Foundation. How does prescription drug spending and use compare across large employer plans, medicare part D, and Medicaid?; 2019. Available from: https://www.kff.org/medicare/issue-brief/how-does-prescription-drug-spending-and-use-compare-across-large-employer-plans-medicare-part-d-and-medicaid/. Accessed January 12, 2023.
   Google Scholar
• Kaiser Family Foundation. 2020 employer health benefits survey; 2020. Available from: https://files.kff.org/attachment/Report-Employer-Health-Benefits-2020-Annual-Survey.pdf. Accessed January 12, 2023.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Health-Plan and employer-based wellness programs to reduce diabetes risk: the Kaiser Permanente Northern California NEXT-D study; 2013. Available from: https://www.cdc.gov/pcd/issues/2013/pdf/12_0146.pdf. Accessed January 12, 2023.
   Google Scholar
• Abraham JM, Feldman R, Nyman JA, Barleen N. What factors influence participation in an exercise-focused, employer-based wellness program? INQUIRY. 2011;48(3):221–241. doi:10.5034/inquiryjrnl_48.03.01
   PubMed Web of Science ®Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.3224
   PubMed Web of Science ®Google Scholar
• Kolla BP, He JP, Mansukhani MP, Frye MA, Merikangas K. Excessive sleepiness and associated symptoms in the U.S. adult population: prevalence, correlates, and comorbidity. Sleep Health. 2020;6(1):79–87. doi:10.1016/j.sleh.2019.09.004
   PubMed Web of Science ®Google Scholar
• Olesen J, Dodick DW, Ducros A, et al. Headache classification committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. doi:10.1177/0333102417738202
   Web of Science ®Google Scholar
• Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum. 1990;33(2):160–172. doi:10.1002/art.1780330203
   PubMed Web of Science ®Google Scholar
• Burke MV, Hays JT, Ebbert JO. Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence. Patient Prefer Adherence. 2016;10:435–441. doi:10.2147/PPA.S83469
   PubMed Web of Science ®Google Scholar
• Tonstad S, Arons C, Rollema H, et al. Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations. Curr Med Res Opin. 2020;36(5):713–730. doi:10.1080/03007995.2020.1729708
   PubMed Web of Science ®Google Scholar
• Chapman JL, Kempler L, Chang CL, et al. Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial. Thorax. 2014;69(3):274. doi:10.1136/thoraxjnl-2013-203796
   PubMed Web of Science ®Google Scholar
• Golicki D, Bala MM, Niewada M, Wierzbicka A. Modafinil for narcolepsy: systematic review and meta-analysis. Med Sci Monit. 2010;16(8):Ra177–Ra186.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Lanteri-Minet M, et al. Long-term efficacy and safety of erenumab. Neurology. 2021;96(22):e2724. doi:10.1212/WNL.0000000000012029
   PubMed Web of Science ®Google Scholar
• Ornello R, Casalena A, Frattale I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):32. doi:10.1186/s10194-020-01102-9
   PubMed Web of Science ®Google Scholar
• Reuter U, Ehrlich M, Gendolla A, et al. Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled Phase 4 trial. Cephalalgia. 2022;42(2):108–118. doi:10.1177/03331024211053571
   PubMed Web of Science ®Google Scholar
• Bhusal S, Diomampo S, Magrey MN. Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia. Drug Healthc Patient Saf. 2016;8:13–23. doi:10.2147/DHPS.S95535
   PubMedGoogle Scholar
• Derry S, Cording M, Wiffen PJ, Law S, Phillips T, Moore RA. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016;9(9):Cd011790. doi:10.1002/14651858.CD011790.pub2
   PubMedGoogle Scholar
• Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology. 2010;49(4):706–715. doi:10.1093/rheumatology/kep432
   PubMed Web of Science ®Google Scholar
• Suehs BT, Davis C, Galaznik A, Joshi AV, Zou KH, Patel NC. Association of out-of-pocket pharmacy costs with adherence to varenicline. J Manag Care Spec Pharm. 2014;20(6):592–600. doi:10.18553/jmcp.2014.20.6.592
   PubMed Web of Science ®Google Scholar
• Yue X, Guo JJ, Wigle PR. Trends in utilization, spending, and prices of smoking-cessation medications in Medicaid programs: 25 Years Empirical Data Analysis, 1991–2015. Am Health Drug Benefits. 2018;11(6):275–285.
   PubMed Web of Science ®Google Scholar
• Zeng F, Chen CI, Mastey V, Zou KH, Harnett J, Patel BV. Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims. Clin Ther. 2011;33(2):225–234. doi:10.1016/j.clinthera.2011.02.013
   PubMed Web of Science ®Google Scholar
• Hypersomnia Foundation. Our struggle for prescription drug coverage – 2019 survey results. Available from: https://www.hypersomniafoundation.org/our-struggle-for-prescription-drug-coverage-2019-survey-results/. Accessed March 9, 2022.
   Google Scholar
• Beasley D. Amgen’s new migraine drug hits insurance hurdles. Reuters. Available from: https://www.reuters.com/article/us-amgen-pricing-migraine/amgens-new-migraine-drug-hits-insurance-hurdles-idUSKBN1KG0CT. Accessed March 9, 2022.
   Google Scholar
• Pearson SD, Beinfeld M, Fluetsch N, Grady M, Shah K, Emond SK. Assessment of barriers to fair access; 2021. Available from: https://icer.org/wp-content/uploads/2021/05/Barriers-to-Fair-Access-Assessment-Final-Report-120121.pdf. Accessed January 12, 2023.
   Google Scholar
• Tepper DE. Calcitonin gene-related protein (CGRP)-targeted treatments for migraine prevention. Headache. 2019;59(3):477–480. doi:10.1111/head.13492
   PubMed Web of Science ®Google Scholar
• Stacey BR, Liss J, Behar R, et al. A systematic review of the effectiveness of policies restricting access to pregabalin. BMC Health Serv Res. 2017;17(1):600. doi:10.1186/s12913-017-2503-x
   PubMedGoogle Scholar
• Barnett PG, Ignacio RV, Kim HM, et al. Cost-effectiveness of real-world administration of tobacco pharmacotherapy in the United States Veterans Health Administration. Addiction. 2019;114(8):1436–1445. doi:10.1111/add.14621
   PubMed Web of Science ®Google Scholar
• Lee LJ, Li Q, Bruno M, et al. Healthcare costs of smokers using varenicline versus nicotine-replacement therapy patch in the United States: evidence from real-world practice. Adv Ther. 2019;36(2):365–380. doi:10.1007/s12325-018-0858-y
   PubMed Web of Science ®Google Scholar
• Lipton RB, Brennan A, Palmer S, et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. 2018;21(7):666–675. doi:10.1080/13696998.2018.1457533
   PubMed Web of Science ®Google Scholar
• Sussman M, Benner J, Neumann P, Menzin J. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia. 2018;38(10):1644–1657. doi:10.1177/0333102418796842
   PubMed Web of Science ®Google Scholar
• Lloyd A, Boomershine CS, Choy EH, Chandran A, Zlateva G. The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective. J Med Econ. 2012;15(3):481–492. doi:10.3111/13696998.2012.660254
   PubMedGoogle Scholar
• Skaer TL. Fibromyalgia: disease synopsis, medication cost effectiveness and economic burden. Pharmacoeconomics. 2014;32(5):457–466. doi:10.1007/s40273-014-0137-y
   PubMed Web of Science ®Google Scholar
• Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58(4):496–505. doi:10.1111/head.13281
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Smoking and tobacco use. Available from: https://www.cdc.gov/tobacco/data_statistics/index.htm. Accessed May 25, 2021.
   Google Scholar
• National Fibromyalgia Association. Fibromyalgia Prevalence. Available from: https://www.fmaware.org/fibromyalgia-prevalence/. Accessed May 27, 2021.
   Google Scholar
• Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache. 2018;58(5):700–714. doi:10.1111/head.13275
   PubMed Web of Science ®Google Scholar
• Rojewski AM, Baldassarri S, Cooperman NA, et al. Exploring issues of comorbid conditions in people who smoke. Nicotine Tob Res. 2016;18(8):1684–1696. doi:10.1093/ntr/ntw016
   PubMed Web of Science ®Google Scholar
• Benca RM. Narcolepsy and excessive daytime sleepiness: diagnostic considerations, epidemiology, and comorbidities. J Clin Psychiatry. 2007;68(Suppl 13):5–8.
   PubMedGoogle Scholar
• Kim SC, Landon JE, Solomon DH. Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin. Arthritis Care Res. 2013;65(11):1813–1819. doi:10.1002/acr.22071
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. Chantix: package insert; 2019.
   Google Scholar
• Pfizer Inc. Lyrica: package insert; 2020.
   Google Scholar
• Amgen, Inc. Aimovig: package insert; 2021.
   Google Scholar
• Teva Pharmaceuticas USA, Inc. Provigil: package insert; 2015.
   Google Scholar
• IQVIA. US claims–IQVIA PharMetrics Plus. Available from: https://www.iqvia.com/library/fact-sheets/iqvia-pharmetrics-plus. Accessed March 7, 2022.
   Google Scholar
• Dee A, Kearns K, O’Neill C, et al. The direct and indirect costs of both overweight and obesity: a systematic review. BMC Res Notes. 2014;7:242. doi:10.1186/1756-0500-7-242
   PubMedGoogle Scholar
• Frech FQC, Gore M, Zhang Q. Cost implications of early treatment initiation among patients with newly diagnosed fibromyalgia. Am J Pharm Benefits. 2017;9(6):200–207.
   Google Scholar
• Walitt B, Nahin RL, Katz RS, Bergman MJ, Wolfe F. The prevalence and characteristics of fibromyalgia in the 2012 National Health Interview Survey. PLoS One. 2015;10(9):e0138024–e0138024. doi:10.1371/journal.pone.0138024
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Fang J, Vo P, et al. Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study. J Headache Pain. 2021;22(1):27. doi:10.1186/s10194-021-01238-2
   PubMed Web of Science ®Google Scholar
• Yucel A, Thach A, Kumar S, Loden C, Bensink M, Goldfarb N. Estimating the economic burden of migraine on US employers. Am J Manag Care. 2020;26(12):e403–e408. doi:10.37765/ajmc.2020.88547
   PubMed Web of Science ®Google Scholar
• Knauert M, Naik S, Gillespie MB, Kryger M. Clinical consequences and economic costs of untreated obstructive sleep apnea syndrome. World J Otorhinolaryngol Head Neck Surg. 2015;1(1):17–27. doi:10.1016/j.wjorl.2015.08.001
   PubMedGoogle Scholar
• Sassani A, Findley LJ, Kryger M, Goldlust E, George C, Davidson TM. Reducing motor-vehicle collisions, costs, and fatalities by treating obstructive sleep apnea syndrome. Sleep. 2004;27(3):453–458. doi:10.1093/sleep/27.3.453
   PubMed Web of Science ®Google Scholar
• Carlton RR, Lunascek T, Dammerman O. Healthcare resource utilization before and after initiation of armodafinil treatment for wakefulness. Sleep. 2011;34:5.
   Web of Science ®Google Scholar
• Faust E, Pivneva I, Yang K, et al. Real-world treatment profiles, clinical outcomes, and healthcare resource utilization of patients with migraine prescribed erenumab: a multicenter chart-review study of US headache centers. Neurol Ther. 2021;10(1):293–306. doi:10.1007/s40120-021-00245-4
   PubMed Web of Science ®Google Scholar
• Harnett J, Margolis J, Cao Z, et al. Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine. Pain Pract. 2011;11(3):217–229. doi:10.1111/j.1533-2500.2010.00440.x
   PubMed Web of Science ®Google Scholar
• Gartner Glossary. Small and Midsize Business (SMB). Available from: https://www.gartner.com/en/information-technology/glossary/smbs-small-and-midsize-businesses. Accessed March 8, 2022.
   Google Scholar
• U.S. Bureau of Labor Statistics. Occupational employment and wage statistics. Available from: https://www.bls.gov/oes/current/oes_nat.htm. Accessed May 25, 2021.
   Google Scholar
• Bilger M, Finkelstein EA, Kruger E, Tate DF, Linnan LA. The effect of weight loss on health, productivity, and medical expenditures among overweight employees. Med Care. 2013;51(6):471–477. doi:10.1097/MLR.0b013e318286e437
   PubMed Web of Science ®Google Scholar
• Kolotkin RL, Gabriel Smolarz B, Meincke HH, Fujioka K. Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity. Clin Obes. 2018;8(1):1–10. doi:10.1111/cob.12226
   PubMed Web of Science ®Google Scholar
• Managed Markets Insight & Technology LLC. Formulary Lookup; 2021. Available from: www.formularylookup.com. Accessed June 16, 2021.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). NICE recommends new drug for people living with obesity. Available from: https://www.nice.org.uk/news/article/nice-recommends-new-drug-for-people-living-with-obesity. Accessed March 10, 2022.
   Google Scholar
• Halpern MT, Shikiar R, Rentz AM, Khan ZM. Impact of smoking status on workplace absenteeism and productivity. Tob Control. 2001;10(3):233–238. doi:10.1136/tc.10.3.233
   PubMed Web of Science ®Google Scholar
• Reynolds AC, Appleton SL, Gill TK, et al. Sickness absenteeism is associated with sleep problems independent of sleep disorders: results of the 2016 Sleep Health Foundation national survey. Sleep Health. 2017;3(5):357–361. doi:10.1016/j.sleh.2017.06.003
   PubMed Web of Science ®Google Scholar
• Michel P, Dartigues JF, Duru G, Moreau J, Salamon R, Henry P. Incremental absenteeism due to headaches in migraine: results from the Mig-Access French national cohort. Cephalalgia. 1999;19(5):503–510. doi:10.1046/j.1468-2982.1999.019005503.x
   PubMed Web of Science ®Google Scholar
• Chandran A, Schaefer C, Ryan K, Baik R, McNett M, Zlateva G. The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults. J Manag Care Pharm. 2012;18(6):415–426. doi:10.18553/jmcp.2012.18.6.415
   PubMed Web of Science ®Google Scholar